Name of Journal: World Journal of Clinical Oncology
ESPS Manuscript NO: 31780
Manuscript Type: Editorial

Translating new data to the daily practice in second line treatment of renal cell carcinoma: the role of tumor growth rate

Enrique Grande, Olga Martínez-Sáez, Pablo Gajate Borau, Teresa Alonso-Gordo

Abstract

The therapeutic options for patients with metastatic renal cell carcinoma (mRCC) have completely changed during the last ten years. With the sequential
Targeted therapy for metastatic renal cell carcinoma: current treatment ...
https://www.ncbi.nlm.nih.gov › NCBI › Literature › PubMed Central (PMC) - 翻译此页
作者：DYC Heng - 2010 - 被引用次数：11 - 相关文章
The development of new targeted therapies including axitinib, pazopanib, ... Metastatic renal cell cancer (RCC) is estimated to have caused 13,010 ... Agents targeting the vascular endothelial growth factor (VEGF) and .... Thus, sorafenib has assumed largely a second-line or later role in the treatment of metastatic RCC.

Clinical experience with everolimus in the second-line treatment of ...
https://www.ncbi.nlm.nih.gov › NCBI › Literature › PubMed Central (PMC) - 翻译此页
作者：D Alesini - 2015 - 被引用次数：2 - 相关文章
We report data from prospective as well as retrospective and real world data ... Renal cell carcinoma (RCC) accounts for 3% of adult solid tumors with ... As a result, the best second-line therapy remains controversial and in daily clinical practice the ... mTOR has a central role in the regulation of cell growth: it is a downstream ...

Optimal first-line and second-line treatments for metastatic renal cell ...
https://www.ncbi.nlm.nih.gov › NCBI › Literature › PubMed Central (PMC) - 翻译此页
作者：M Sun - 2014 - 被引用次数：11 - 相关文章
2014年10月29日 - In second line, the options consist of everolimus and axitinib. ... The management of metastatic renal cell carcinoma (mRCC) is in constant evolution ... 48% (n=160), for an overall response rate of 79% (n=263) in the sunitinib arm. ... Its pivotal data originate from a first-line Phase III trial that randomized 435 ...

Efficacy and Safety of Sorafenib Therapy on Metastatic Renal Cell ...
Targeted therapy for metastatic renal cell carcinoma: current treatment ...
https://www.ncbi.nlm.nih.gov › NCBI › Literature › PubMed Central (PMC) - 翻译此页
作者：DYC Heng - 2010 - 被引用次数：11 - 相关文章
The development of new targeted therapies including axitinib, pazopanib, ... Metastatic renal cell cancer (RCC) is estimated to have caused 13,010 ... Agents targeting the vascular endothelial growth factor (VEGF) and ... Thus, sorafenib has assumed largely a second-line or later role in the treatment of metastatic RCC.

Systemic Therapy for Metastatic Renal Cell Carcinoma: A Review and ...
https://www.ncbi.nlm.nih.gov › NCBI › Literature › PubMed Central (PMC) - 翻译此页
作者：JE Logan - 2012 - 被引用次数：9 - 相关文章
The treatment of metastatic renal cell carcinoma (mRCC) has progressed toward the ... Response rates with high-dose IL-2 have been reported at 20%, and ... Elucidation of the von Hippel-Lindau (VHL) tumor suppressor and its role in RCC ... 2011 for second-line treatment of patients with mRCC, based on phase III data ...

Clinical experience with everolimus in the second-line treatment of ...
https://www.ncbi.nlm.nih.gov › NCBI › Literature › PubMed Central (PMC) - 翻译此页
作者：D Alesini - 2015 - 被引用次数：2 - 相关文章
We report data from prospective as well as retrospective and real world data ... Renal cell carcinoma (RCC) accounts for 3% of adult solid tumors with ... As a result, the best second-line therapy remains controversial and in daily clinical practice the ... mTOR has a central role in the regulation of cell growth: it is a downstream ...